Physician profile
Hannah Ashlock
NPI 1760005359
$2,907.84
in general payments reported to CMS, 2019-2025
23 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.13 · 2022: $615 · 2023: $1,101 · 2024: $875 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,243.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $775.53 | 2022-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $616.14 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $170.75 | 2022-2024 | Repatha, Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $129.93 | 2022-2024 | |
| Lilly USA, LLC | $126.42 | 2021-2024 | Zepbound, Mounjaro |
| Insulet Corporation | $122.63 | 2023-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $122.59 | 2022-2024 | |
| Corcept Therapeutics | $121.17 | 2023-2024 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.54 | 2022-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $105.04 | 2022-2024 | Gvoke Hypopen |
| Medtronic, INC. | $91.94 | 2022-2024 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Radius Health, INC. | $74.55 | 2023-2024 | Tymlos |
| Abbvie INC. | $49.74 | 2023 | |
| Kyowa Kirin, INC. | $46.74 | 2023-2024 | Crysvita |
| Tandem Diabetes Care, INC. | $39.09 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $37.36 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $28.52 | 2023 | Breztri |
| Horizon Therapeutics Plc | $28.11 | 2023 | Tepezza |
| Merck Sharp & Dohme LLC | $24.54 | 2022-2023 | Steglatro, Segluromet, Steglujan |
| Amarin Pharma, INC. | $24.09 | 2021 | |
| Beta Bionics, INC. | $23.85 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amryt Pharma Holdings LTD | $18.89 | 2023 | Myalept |
| Janssen Pharmaceuticals, INC | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Ashlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.